ID   FA9_HUMAN               Reviewed;         461 AA.
AC   P00740; A8K9N4; F2RM36; Q5FBE1; Q5JYJ8;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2005, sequence version 2.
DT   22-JUL-2015, entry version 216.
DE   RecName: Full=Coagulation factor IX {ECO:0000303|PubMed:3857619};
DE            EC=3.4.21.22 {ECO:0000269|PubMed:12444082, ECO:0000269|PubMed:20121197, ECO:0000269|PubMed:20121198, ECO:0000269|PubMed:2592373};
DE   AltName: Full=Christmas factor;
DE   AltName: Full=Plasma thromboplastin component;
DE            Short=PTC;
DE   Contains:
DE     RecName: Full=Coagulation factor IXa light chain;
DE   Contains:
DE     RecName: Full=Coagulation factor IXa heavy chain;
DE   Flags: Precursor;
GN   Name=F9;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=6959130; DOI=10.1073/pnas.79.21.6461;
RA   Kurachi K., Davie E.W.;
RT   "Isolation and characterization of a cDNA coding for human factor
RT   IX.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:6461-6464(1982).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=6687940; DOI=10.1093/nar/11.8.2325;
RA   Jaye M., de la Salle H., Schamber F., Balland A., Kohli V.,
RA   Findeli A., Tolstoshev P., Lecocq J.-P.;
RT   "Isolation of a human anti-haemophilic factor IX cDNA clone using a
RT   unique 52-base synthetic oligonucleotide probe deduced from the amino
RT   acid sequence of bovine factor IX.";
RL   Nucleic Acids Res. 11:2325-2335(1983).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-194.
RX   PubMed=6329734;
RA   Anson D.S., Choo K.H., Rees D.J.G., Giannelli F., Gould K.G.,
RA   Huddleston J.A., Brownlee G.G.;
RT   "The gene structure of human anti-haemophilic factor IX.";
RL   EMBO J. 3:1053-1060(1984).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-194.
RX   PubMed=2994716; DOI=10.1021/bi00335a049;
RA   Yoshitake S., Schach B.G., Foster D.C., Davie E.W., Kurachi K.;
RT   "Nucleotide sequence of the gene for human factor IX (antihemophilic
RT   factor B).";
RL   Biochemistry 24:3736-3750(1985).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ALA-194, SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=3857619; DOI=10.1073/pnas.82.9.2847;
RA   McGraw R.A., Davis L.M., Noyes C.M., Lundblad R.L., Roberts H.R.,
RA   Graham J.B., Stafford D.W.;
RT   "Evidence for a prevalent dimorphism in the activation peptide of
RT   human coagulation factor IX.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:2847-2851(1985).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RC   TISSUE=Liver;
RA   Sata S., Yonemitsu Y., Nakagawa K., Sueishi K.;
RT   "Alternative splicing variant of Homo sapiens coagulation factor IX
RT   lacking EGF like domain.";
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PRO-461.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (AUG-2002) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RA   Nguyen D.T., Nguyen P.V., Nong H.V.;
RT   "Homo sapiens coagulation factor IX (F9), mRNA.";
RL   Submitted (MAR-2011) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 30-84, VARIANT HEMB GLN-43,
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND PROTEOLYTIC
RP   CLEAVAGE.
RX   PubMed=8295821;
RA   de la Salle C., Charmantier J.L., Ravanat C., Ohlmann P.,
RA   Hartmann M.L., Schuhler S., Bischoff R., Ebel C., Roecklin D.,
RA   Balland A.;
RT   "The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation by
RT   factor XIa.";
RL   Nouv. Rev. Fr. Hematol. 35:473-480(1993).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 36-326 (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=6089357; DOI=10.1007/BF01534851;
RA   Jagadeeswaran P., Lavelle D.E., Kaul R., Mohandas T., Warren S.T.;
RT   "Isolation and characterization of human factor IX cDNA:
RT   identification of Taq I polymorphism and regional assignment.";
RL   Somat. Cell Mol. Genet. 10:465-473(1984).
RN   [15]
RP   PROTEIN SEQUENCE OF 47-461, VARIANT HEMB TRP-226, FUNCTION, CATALYTIC
RP   ACTIVITY, PROTEOLYTIC CLEAVAGE, SUBCELLULAR LOCATION, SUBUNIT, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=2592373;
RA   Suehiro K., Kawabata S., Miyata T., Takeya H., Takamatsu J., Ogata K.,
RA   Kamiya T., Saito H., Niho Y., Iwanaga S.;
RT   "Blood clotting factor IX BM Nagoya. Substitution of arginine 180 by
RT   tryptophan and its activation by alpha-chymotrypsin and rat mast cell
RT   chymase.";
RL   J. Biol. Chem. 264:21257-21265(1989).
RN   [16]
RP   PROTEIN SEQUENCE OF 47-52, TISSUE SPECIFICITY, SUBCELLULAR LOCATION,
RP   CHARACTERIZATION OF VARIANTS HEMB GLN-43; LEU-43 AND TRP-43,
RP   CALCIUM-BINDING, AND PROTEOLYTIC CLEAVAGE.
RX   PubMed=9169594;
RA   Wojcik E.G., Van Den Berg M., Poort S.R., Bertina R.M.;
RT   "Modification of the N-terminus of human factor IX by defective
RT   propeptide cleavage or acetylation results in a destabilized calcium-
RT   induced conformation: effects on phospholipid binding and activation
RT   by factor XIa.";
RL   Biochem. J. 323:629-636(1997).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 290-359.
RX   PubMed=3340835; DOI=10.1126/science.3340835;
RA   Stoflet E.S., Koeberl D.D., Sarkar G., Sommer S.S.;
RT   "Genomic amplification with transcript sequencing.";
RL   Science 239:491-494(1988).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 444-461.
RX   PubMed=8236150;
RA   de la Salle C., Charmantier J.L., Baas M.-J., Schwartz A.,
RA   Wiesel M.L., Grunebaum L., Cazenave J.-P.;
RT   "A deletion located in the 3' non translated part of the factor IX
RT   gene responsible for mild haemophilia B.";
RL   Thromb. Haemost. 70:370-371(1993).
RN   [19]
RP   HYDROXYLATION AT ASP-110.
RX   PubMed=6688526; DOI=10.1016/0006-291X(83)90961-0;
RA   McMullen B.A., Fujikawa K., Kisiel W.;
RT   "The occurrence of beta-hydroxyaspartic acid in the vitamin K-
RT   dependent blood coagulation zymogens.";
RL   Biochem. Biophys. Res. Commun. 115:8-14(1983).
RN   [20]
RP   PROTEOLYTIC PROCESSING, AND ACTIVE SITE.
RX   PubMed=659613; DOI=10.1172/JCI109073;
RA   di Scipio R.G., Kurachi K., Davie E.W.;
RT   "Activation of human factor IX (Christmas factor).";
RL   J. Clin. Invest. 61:1528-1538(1978).
RN   [21]
RP   CALCIUM-BINDING, AND DOMAIN.
RX   PubMed=6425296;
RA   Morita T., Isaacs B.S., Esmon C.T., Johnson A.E.;
RT   "Derivatives of blood coagulation factor IX contain a high affinity
RT   Ca2+-binding site that lacks gamma-carboxyglutamic acid.";
RL   J. Biol. Chem. 259:5698-5704(1984).
RN   [22]
RP   ERRATUM.
RA   Morita T., Isaacs B.S., Esmon C.T., Johnson A.E.;
RL   J. Biol. Chem. 260:2583-2583(1985).
RN   [23]
RP   STRUCTURE OF CARBOHYDRATE ON SER-99.
RX   PubMed=2511201;
RA   Nishimura H., Kawabata S., Kisiel W., Hase S., Ikenaka T., Takao T.,
RA   Shimonishi Y., Iwanaga S.;
RT   "Identification of a disaccharide (Xyl-Glc) and a trisaccharide (Xyl2-
RT   Glc) O-glycosidically linked to a serine residue in the first
RT   epidermal growth factor-like domain of human factors VII and IX and
RT   protein Z and bovine protein Z.";
RL   J. Biol. Chem. 264:20320-20325(1989).
RN   [24]
RP   STRUCTURE OF CARBOHYDRATE ON SER-99.
RX   PubMed=2129367;
RA   Iwanaga S., Nishimura H., Kawabata S., Kisiel W., Hase S., Ikenaka T.;
RT   "A new trisaccharide sugar chain linked to a serine residue in the
RT   first EGF-like domain of clotting factors VII and IX and protein Z.";
RL   Adv. Exp. Med. Biol. 281:121-131(1990).
RN   [25]
RP   FUNCTION, AND PROTEOLYTIC CLEAVAGE.
RX   PubMed=1730085;
RA   Rawala-Sheikh R., Ahmad S.S., Monroe D.M., Roberts H.R., Walsh P.N.;
RT   "Role of gamma-carboxyglutamic acid residues in the binding of factor
RT   IXa to platelets and in factor-X activation.";
RL   Blood 79:398-405(1992).
RN   [26]
RP   STRUCTURE OF CARBOHYDRATE ON SER-107.
RX   PubMed=1517205;
RA   Nishimura H., Takao T., Hase S., Shimonishi Y., Iwanaga S.;
RT   "Human factor IX has a tetrasaccharide O-glycosidically linked to
RT   serine 61 through the fucose residue.";
RL   J. Biol. Chem. 267:17520-17525(1992).
RN   [27]
RP   GLYCOSYLATION AT THR-205 AND THR-215.
RX   PubMed=8172892; DOI=10.1021/bi00183a021;
RA   Agarwala K.L., Kawabata S., Takao T., Murata H., Shimonishi Y.,
RA   Nishimura H., Iwanaga S.;
RT   "Activation peptide of human factor IX has oligosaccharides O-
RT   glycosidically linked to threonine residues at 159 and 169.";
RL   Biochemistry 33:5167-5171(1994).
RN   [28]
RP   PHOSPHORYLATION AT SER-114.
RA   Harris R.J., Papac D.I., Truong L., Smith K.J.;
RT   "Partial phosphorylation of serine-68 in EGF-1 of human factor IX.";
RL   (In) Proceedings of XIth international conference on methods in
RL   protein structure analysis, pp.50-50, Annecy (1996).
RN   [29]
RP   SULFATION AT TYR-201, AND PHOSPHORYLATION AT SER-204.
RX   PubMed=11133752; DOI=10.1182/blood.V97.1.130;
RA   Arruda V.R., Hagstrom J.N., Deitch J., Heiman-Patterson T.,
RA   Camire R.M., Chu K., Fields P.A., Herzog R.W., Couto L.B.,
RA   Larson P.J., High K.A.;
RT   "Posttranslational modifications of recombinant myotube-synthesized
RT   human factor IX.";
RL   Blood 97:130-138(2001).
RN   [30]
RP   CATALYTIC ACTIVITY, AND MUTAGENESIS OF TYR-305; LYS-311; TYR-312 AND
RP   TYR-391.
RX   PubMed=12444082; DOI=10.1074/jbc.M210722200;
RA   Sichler K., Kopetzki E., Huber R., Bode W., Hopfner K.P.,
RA   Brandstetter H.;
RT   "Physiological fIXa activation involves a cooperative conformational
RT   rearrangement of the 99-loop.";
RL   J. Biol. Chem. 278:4121-4126(2003).
RN   [31]
RP   GLYCOSYLATION AT SER-99.
RX   PubMed=21949356; DOI=10.1073/pnas.1109696108;
RA   Takeuchi H., Fernandez-Valdivia R.C., Caswell D.S., Nita-Lazar A.,
RA   Rana N.A., Garner T.P., Weldeghiorghis T.K., Macnaughtan M.A.,
RA   Jafar-Nejad H., Haltiwanger R.S.;
RT   "Rumi functions as both a protein O-glucosyltransferase and a protein
RT   O-xylosyltransferase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:16600-16605(2011).
RN   [32]
RP   GLYCOSYLATION AT THR-85; SER-99; SER-107; THR-205; THR-215 AND
RP   THR-225, PHOSPHORYLATION AT SER-204 AND THR-205, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=25456591; DOI=10.1016/j.chroma.2014.10.046;
RA   Huang L.J., Lin J.H., Tsai J.H., Chu Y.Y., Chen Y.W., Chen S.L.,
RA   Chen S.H.;
RT   "Identification of protein O-glycosylation site and corresponding
RT   glycans using liquid chromatography-tandem mass spectrometry via
RT   mapping accurate mass and retention time shift.";
RL   J. Chromatogr. A 1371:136-145(2014).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [34]
RP   STRUCTURE BY NMR OF 47-93.
RX   PubMed=7713897; DOI=10.1074/jbc.270.14.7980;
RA   Freedman S.J., Furie B.C., Furie B., Baleja J.D.;
RT   "Structure of the metal-free gamma-carboxyglutamic acid-rich membrane
RT   binding region of factor IX by two-dimensional NMR spectroscopy.";
RL   J. Biol. Chem. 270:7980-7987(1995).
RN   [35]
RP   STRUCTURE BY NMR OF 47-93.
RX   PubMed=7547952; DOI=10.1021/bi00038a005;
RA   Freedman S.J., Furie B.C., Furie B., Baleja J.D.;
RT   "Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich
RT   domain of factor IX.";
RL   Biochemistry 34:12126-12137(1995).
RN   [36]
RP   STRUCTURE BY NMR OF 47-93.
RX   PubMed=8663165; DOI=10.1074/jbc.271.27.16227;
RA   Freedman S.J., Blostein M.D., Baleja J.D., Jacobs M., Furie B.C.,
RA   Furie B.;
RT   "Identification of the phospholipid binding site in the vitamin K-
RT   dependent blood coagulation protein factor IX.";
RL   J. Biol. Chem. 271:16227-16236(1996).
RN   [37]
RP   STRUCTURE BY NMR OF 47-93.
RX   PubMed=9047312; DOI=10.1021/bi962250r;
RA   Li L., Darden T.A., Freedman S.J., Furie B.C., Furie B., Baleja J.D.,
RA   Smith H., Hiskey R.G., Pedersen L.G.;
RT   "Refinement of the NMR solution structure of the gamma-carboxyglutamic
RT   acid domain of coagulation factor IX using molecular dynamics
RT   simulation with initial Ca2+ positions determined by a genetic
RT   algorithm.";
RL   Biochemistry 36:2132-2138(1997).
RN   [38]
RP   STRUCTURE BY NMR OF 91-133.
RX   PubMed=1854745; DOI=10.1021/bi00244a006;
RA   Huang L.H., Cheng H., Pardi A., Tam J.P., Sweeney W.V.;
RT   "Sequence-specific 1H NMR assignments, secondary structure, and
RT   location of the calcium binding site in the first epidermal growth
RT   factor like domain of blood coagulation factor IX.";
RL   Biochemistry 30:7402-7409(1991).
RN   [39]
RP   STRUCTURE BY NMR OF 92-130, AND DISULFIDE BOND.
RX   PubMed=1304885; DOI=10.1002/pro.5560010109;
RA   Baron M., Norman D.G., Harvey T.S., Handford P.A., Mayhew M.,
RA   Tse A.G.D., Brownlee G.G., Campbell I.D.C.;
RT   "The three-dimensional structure of the first EGF-like module of human
RT   factor IX: comparison with EGF and TGF-alpha.";
RL   Protein Sci. 1:81-90(1992).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 92-130 IN COMPLEX WITH
RP   CALCIUM, AND DISULFIDE BOND.
RX   PubMed=7606779; DOI=10.1016/0092-8674(95)90059-4;
RA   Rao Z., Handford P., Mayhew M., Knott V., Brownlee G.G., Stuart D.;
RT   "The structure of a Ca(2+)-binding epidermal growth factor-like
RT   domain: its role in protein-protein interactions.";
RL   Cell 82:131-141(1995).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 133-461 IN COMPLEX WITH
RP   CALCIUM.
RX   PubMed=10467148; DOI=10.1016/S0969-2126(99)80125-7;
RA   Hopfner K.-P., Lang A., Karcher A., Sichler K., Kopetzki E.,
RA   Brandstetter H., Huber R., Bode W., Engh R.A.;
RT   "Coagulation factor IXa: the relaxed conformation of Tyr99 blocks
RT   substrate binding.";
RL   Structure 7:989-996(1999).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 47-91 IN COMPLEX WITH
RP   CALCIUM.
RX   PubMed=14722079; DOI=10.1074/jbc.M314011200;
RA   Huang M., Furie B.C., Furie B.;
RT   "Crystal structure of the calcium-stabilized human factor IX Gla
RT   domain bound to a conformation-specific anti-factor IX antibody.";
RL   J. Biol. Chem. 279:14338-14346(2004).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 133-191 AND 227-461 OF
RP   MUTANTS PHE-305/THR-311/ALA-365/THR-391 IN COMPLEX WITH CALCIUM AND
RP   SYNTHETIC INHIBITOR, ACTIVE SITE, DISULFIDE BOND, SUBUNIT, AND
RP   PROTEOLYTIC CLEAVAGE.
RX   PubMed=20004170; DOI=10.1016/j.str.2009.10.011;
RA   Zogg T., Brandstetter H.;
RT   "Structural basis of the cofactor- and substrate-assisted activation
RT   of human coagulation factor IXa.";
RL   Structure 17:1669-1678(2009).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 133-461 IN COMPLEX WITH
RP   CALCIUM, FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, AND DISULFIDE BOND.
RX   PubMed=20121198; DOI=10.1021/jm901475e;
RA   Wang S., Beck R., Blench T., Burd A., Buxton S., Malic M., Ayele T.,
RA   Shaikh S., Chahwala S., Chander C., Holland R., Merette S., Zhao L.,
RA   Blackney M., Watts A.;
RT   "Studies of benzothiophene template as potent factor IXa (FIXa)
RT   inhibitors in thrombosis.";
RL   J. Med. Chem. 53:1465-1472(2010).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.62 ANGSTROMS) OF 133-188 AND 227-461 IN
RP   COMPLEX WITH CALCIUM, FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, AND
RP   DISULFIDE BOND.
RX   PubMed=20121197; DOI=10.1021/jm901476x;
RA   Wang S., Beck R., Burd A., Blench T., Marlin F., Ayele T., Buxton S.,
RA   Dagostin C., Malic M., Joshi R., Barry J., Sajad M., Cheung C.,
RA   Shaikh S., Chahwala S., Chander C., Baumgartner C., Holthoff H.P.,
RA   Murray E., Blackney M., Giddings A.;
RT   "Structure based drug design: development of potent and selective
RT   factor IXa (FIXa) inhibitors.";
RL   J. Med. Chem. 53:1473-1482(2010).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 131-188 AND 227-461 IN
RP   COMPLEX WITH SERPINC1 AND CALCIUM, DISULFIDE BOND, PROTEOLYTIC
RP   CLEAVAGE, AND SUBUNIT.
RX   PubMed=20080729; DOI=10.1073/pnas.0910144107;
RA   Johnson D.J., Langdown J., Huntington J.A.;
RT   "Molecular basis of factor IXa recognition by heparin-activated
RT   antithrombin revealed by a 1.7-A structure of the ternary complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:645-650(2010).
RN   [47]
RP   MOLECULAR PATHOLOGY OF HEMB B.
RX   PubMed=2743975;
RA   Green P.M., Bentley D.R., Mibashan R.S., Nilsson I.M., Giannelli F.;
RT   "Molecular pathology of haemophilia B.";
RL   EMBO J. 8:1067-1072(1989).
RN   [48]
RP   REVIEW ON HEMB VARIANTS.
RX   PubMed=1634040;
RA   Sommer S.S.;
RT   "Assessing the underlying pattern of human germline mutations: lessons
RT   from the factor IX gene.";
RL   FASEB J. 6:2767-2774(1992).
RN   [49]
RP   REVIEW ON HEMB VARIANTS.
RX   PubMed=8392713; DOI=10.1093/nar/21.13.3075;
RA   Giannelli F., Green P.M., High K.A., Sommer S., Poon M.-C., Ludwig M.,
RA   Schwaab R., Reitsma P.H., Goossens M., Yoshioka A., Brownlee G.G.;
RT   "Haemophilia B: database of point mutations and short additions and
RT   deletions -- fourth edition, 1993.";
RL   Nucleic Acids Res. 21:3075-3087(1993).
RN   [50]
RP   VARIANT HEMB HIS-191.
RX   PubMed=6603618; DOI=10.1073/pnas.80.14.4200;
RA   Noyes C.M., Griffith M.J., Roberts H.R., Lundblad R.L.;
RT   "Identification of the molecular defect in factor IX Chapel Hill:
RT   substitution of histidine for arginine at position 145.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:4200-4202(1983).
RN   [51]
RP   VARIANT HEMB GLN-43, AND CHARACTERIZATION OF VARIANT HEMB GLN-43.
RX   PubMed=3009023; DOI=10.1016/0092-8674(86)90319-3;
RA   Bentley A.K., Rees D.J., Rizza C., Brownlee G.G.;
RT   "Defective propeptide processing of blood clotting factor IX caused by
RT   mutation of arginine to glutamine at position -4.";
RL   Cell 45:343-348(1986).
RN   [52]
RP   VARIANT HEMB GLY-93.
RX   PubMed=3790720;
RA   Davis L.M., McGraw R.A., Ware J.L., Roberts H.R., Stafford D.W.;
RT   "Factor IXAlabama: a point mutation in a clotting protein results in
RT   hemophilia B.";
RL   Blood 69:140-143(1987).
RN   [53]
RP   VARIANT HEMB THR-443.
RX   PubMed=3401602;
RA   Ware J., Davis L., Frazier D., Bajaj S.P., Stafford D.W.;
RT   "Genetic defect responsible for the dysfunctional protein: factor IX
RT   (Long Beach).";
RL   Blood 72:820-822(1988).
RN   [54]
RP   VARIANT HEMB VAL-436.
RX   PubMed=3243764;
RA   Sugimoto M., Miyata T., Kawabata S., Yoshioka A., Fukui H.,
RA   Takahashi H., Iwanaga S.;
RT   "Blood clotting factor IX Niigata: substitution of alanine-390 by
RT   valine in the catalytic domain.";
RL   J. Biochem. 104:878-880(1988).
RN   [55]
RP   VARIANT HEMB GLN-226.
RX   PubMed=2713493;
RA   Monroe D.M., McCord D.M., Huang M.N., High K.A., Lundblad R.L.,
RA   Kasper C.K., Roberts H.R.;
RT   "Functional consequences of an arginine180 to glutamine mutation in
RT   factor IX Hilo.";
RL   Blood 73:1540-1544(1989).
RN   [56]
RP   VARIANT HEMB ARG-442.
RX   PubMed=2714791; DOI=10.1016/0888-7543(89)90330-3;
RA   Attree O., Vidaud D., Vidaud M., Amselem S., Lavergne J.-M.,
RA   Goossens M.;
RT   "Mutations in the catalytic domain of human coagulation factor IX:
RT   rapid characterization by direct genomic sequencing of DNA fragments
RT   displaying an altered melting behavior.";
RL   Genomics 4:266-272(1989).
RN   [57]
RP   VARIANTS HEMB GLN-75; ASP-79; TRP-268; THR-279; SER-306; MET-342;
RP   ARG-357 AND ARG-453, AND VARIANT PHE-7.
RX   PubMed=2773937;
RA   Koeberl D.D., Bottema C.D., Buerstedde J.-M., Sommer S.S.;
RT   "Functionally important regions of the factor IX gene have a low rate
RT   of polymorphism and a high rate of mutation in the dinucleotide CpG.";
RL   Am. J. Hum. Genet. 45:448-457(1989).
RN   [58]
RP   VARIANT HEMB CYS-191.
RX   PubMed=2775660; DOI=10.1111/j.1365-2141.1989.tb04323.x;
RA   Liddell M.B., Peake I.R., Taylor S.A., Lillicrap D.P., Giddings J.C.,
RA   Bloom A.L.;
RT   "Factor IX Cardiff: a variant factor IX protein that shows abnormal
RT   activation is caused by an arginine to cysteine substitution at
RT   position 145.";
RL   Br. J. Haematol. 72:556-560(1989).
RN   [59]
RP   VARIANT HEMB PHE-228.
RX   PubMed=2753873;
RA   Sakai T., Yoshioka A., Yamamoto K., Niinomi K., Fujimura Y., Fukui H.,
RA   Miyata T., Iwanaga S.;
RT   "Blood clotting factor IX Kashihara: amino acid substitution of
RT   valine-182 by phenylalanine.";
RL   J. Biochem. 105:756-759(1989).
RN   [60]
RP   VARIANT HEMB GLN-43.
RX   PubMed=2738071;
RA   Ware J., Diuguid D.L., Liebman H.A., Rabiet M.J., Kasper C.K.,
RA   Furie B.C., Furie B., Stafford D.W.;
RT   "Factor IX San Dimas. Substitution of glutamine for Arg-4 in the
RT   propeptide leads to incomplete gamma-carboxylation and altered
RT   phospholipid binding properties.";
RL   J. Biol. Chem. 264:11401-11406(1989).
RN   [61]
RP   VARIANTS HEMB LYS-73; SER-106 AND GLN-294.
RX   PubMed=2472424; DOI=10.1172/JCI114130;
RA   Chen S.H., Thompson A.R., Zhang M., Scott C.R.;
RT   "Three point mutations in the factor IX genes of five hemophilia B
RT   patients. Identification strategy using localization by altered
RT   epitopes in their hemophilic proteins.";
RL   J. Clin. Invest. 84:113-118(1989).
RN   [62]
RP   VARIANT HEMB VAL-73.
RX   PubMed=2339358;
RA   Wang N.S., Zhang M., Thompson A.R., Chen S.H.;
RT   "Factor IX Chongqing: a new mutation in the calcium-binding domain of
RT   factor IX resulting in severe hemophilia B.";
RL   Thromb. Haemost. 63:24-26(1990).
RN   [63]
RP   VARIANT HEMB LEU-228.
RX   PubMed=2372509; DOI=10.1111/j.1365-2141.1990.tb02652.x;
RA   Taylor S.A., Liddell M.B., Peake I.R., Bloom A.L., Lillicrap D.P.;
RT   "A mutation adjacent to the beta cleavage site of factor IX (valine
RT   182 to leucine) results in mild haemophilia Bm.";
RL   Br. J. Haematol. 75:217-221(1990).
RN   [64]
RP   VARIANTS HEMB GLN-226; TRP-226; PHE-227 AND THR-414.
RX   PubMed=2162822;
RA   Bertina R.M., van der Linden I.K., Mannucci P.M., Reinalda-Poot H.H.,
RA   Cupers R., Poort S.R., Reitsma P.H.;
RT   "Mutations in hemophilia Bm occur at the Arg180-Val activation site or
RT   in the catalytic domain of factor IX.";
RL   J. Biol. Chem. 265:10876-10883(1990).
RN   [65]
RP   VARIANT HEMB GLU-357.
RX   PubMed=1958666; DOI=10.1021/bi00111a014;
RA   Miyata T., Sakai T., Sugimoto M., Naka H., Yamamoto K., Yoshioka A.,
RA   Fukui H., Mitsui K., Kamiya K., Umeyama H., Iwanaga S.;
RT   "Factor IX Amagasaki: a new mutation in the catalytic domain resulting
RT   in the loss of both coagulant and esterase activities.";
RL   Biochemistry 30:11286-11291(1991).
RN   [66]
RP   VARIANT HEMB THR-443.
RX   PubMed=1902289; DOI=10.1093/nar/19.5.1165;
RA   Sarkar G., Cassady J.D., Pyeritz R.E., Gilchrist G.S., Sommer S.S.;
RT   "Isoleucine-397 is changed to threonine in two females with hemophilia
RT   B.";
RL   Nucleic Acids Res. 19:1165-1165(1991).
RN   [67]
RP   VARIANTS HEMB VAL-291; GLN-294; HIS-410; GLY-411 AND ILE-411.
RX   PubMed=1346975;
RA   Ludwig M., Sabharwal A.K., Brackmann H.H., Olek K., Smith K.J.,
RA   Birktoft J.J., Bajaj S.P.;
RT   "Hemophilia B caused by five different nondeletion mutations in the
RT   protease domain of factor IX.";
RL   Blood 79:1225-1232(1992).
RN   [68]
RP   VARIANT HEMB SER-252.
RX   PubMed=1615485;
RA   Taylor S.A., Duffin J., Cameron C., Teitel J., Garvey B.,
RA   Lillicrap D.P.;
RT   "Characterization of the original Christmas disease mutation (cysteine
RT   206-->serine): from clinical recognition to molecular pathogenesis.";
RL   Thromb. Haemost. 67:63-65(1992).
RN   [69]
RP   VARIANTS HEMB ARG-253; GLN-294; GLN-379; PRO-426 AND ILE-TYR-THR-445
RP   INS.
RX   PubMed=8257988; DOI=10.1002/humu.1380020506;
RA   David D., Rosa H.A.V., Pemberton S., Diniz M.J., Campos M.,
RA   Lavinha J.;
RT   "Single-strand conformation polymorphism (SSCP) analysis of the
RT   molecular pathology of hemophilia B.";
RL   Hum. Mutat. 2:355-361(1993).
RN   [70]
RP   VARIANTS HEMB HIS-191; GLY-226; THR-279; GLN-379; GLU-419 AND GLN-449.
RX   PubMed=8076946; DOI=10.1007/BF00208285;
RA   Aguilar-Martinez P., Romey M.-C., Schved J.-F., Gris J.-C.,
RA   Demaille J., Claustres M.;
RT   "Factor IX gene mutations causing haemophilia B: comparison of SSC
RT   screening versus systematic DNA sequencing and diagnostic
RT   applications.";
RL   Hum. Genet. 94:287-290(1994).
RN   [71]
RP   VARIANT HEMB GLU-419.
RX   PubMed=8199596; DOI=10.1002/humu.1380030211;
RA   Aguilar-Martinez P., Romey M.-C., Gris J.-C., Schved J.-F.,
RA   Demaille J., Claustres M.;
RT   "A novel mutation (Val-373 to Glu) in the catalytic domain of factor
RT   IX, resulting in moderately/severe hemophilia B in a southern French
RT   patient.";
RL   Hum. Mutat. 3:156-158(1994).
RN   [72]
RP   VARIANTS HEMB GLN-294 AND ARG-413.
RX   PubMed=7981722; DOI=10.1002/humu.1380040214;
RA   Caglayan S.H., Vielhaber E., Guersel T., Aktuglu G., Sommer S.S.;
RT   "Identification of mutations in four hemophilia B patients of Turkish
RT   origin, including a novel deletion of base 6411.";
RL   Hum. Mutat. 4:163-165(1994).
RN   [73]
RP   VARIANTS HEMB.
RX   PubMed=8680410; DOI=10.1002/humu.1380060410;
RA   Wulff K., Schroeder W., Wehnert M., Herrmann F.H.;
RT   "Twenty-five novel mutations of the factor IX gene in haemophilia B.";
RL   Hum. Mutat. 6:346-348(1995).
RN   [74]
RP   VARIANT WARFARIN SENSITIVITY THR-37.
RX   PubMed=8833911; DOI=10.1172/JCI118956;
RA   Chu K., Wu S.M., Stanley T., Stafford D.W., High K.A.;
RT   "A mutation in the propeptide of factor IX leads to warfarin
RT   sensitivity by a novel mechanism.";
RL   J. Clin. Invest. 98:1619-1625(1996).
RN   [75]
RP   VARIANTS HEMB LYS-113; MET-342; ARG-413 AND VAL-424.
RX   PubMed=9222764;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:1<76::AID-HUMU11>3.3.CO;2-0;
RA   Caglayan S.H., Goekmen Y., Aktuglu G., Guergey A., Sommer S.S.;
RT   "Mutations associated with hemophilia B in Turkish patients.";
RL   Hum. Mutat. 10:76-79(1997).
RN   [76]
RP   VARIANT HEMB PRO-397.
RX   PubMed=9590153;
RX   DOI=10.1002/(SICI)1096-8652(199805)58:1<72::AID-AJH13>3.0.CO;2-7;
RA   Chan V., Chan V.W.Y., Yip B., Chim C.S., Chan T.K.;
RT   "Hemophilia B in a female carrier due to skewed inactivation of the
RT   normal X-chromosome.";
RL   Am. J. Hematol. 58:72-76(1998).
RN   [77]
RP   VARIANTS HEMB ARG-119 AND THR-454.
RX   PubMed=9452115;
RA   David D., Moreira I., Morais S., de Deus G.;
RT   "Five novel factor IX mutations in unrelated hemophilia B patients.";
RL   Hum. Mutat. Suppl. 1:S301-S303(1998).
RN   [78]
RP   VARIANTS HEMB GLN-43; TRP-43; THR-46; SER-106; CYS-115; PHE-155;
RP   GLN-379; GLU-387; VAL-432 AND CYS-450.
RX   PubMed=9600455;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:5<372::AID-HUMU4>3.0.CO;2-M;
RA   Heit J.A., Thorland E.C., Ketterling R.P., Lind T.J., Daniels T.M.,
RA   Zapata R.E., Ordonez S.M., Kasper C.K., Sommer S.S.;
RT   "Germline mutations in Peruvian patients with hemophilia B: pattern of
RT   mutation in Amerindians is similar to the putative endogenous germline
RT   pattern.";
RL   Hum. Mutat. 11:372-376(1998).
RN   [79]
RP   VARIANTS HEMB.
RX   PubMed=10698280;
RA   Wulff K., Bykowska K., Lopaciuk S., Herrmann F.H.;
RT   "Molecular analysis of hemophilia B in Poland: 12 novel mutations of
RT   the factor IX gene.";
RL   Acta Biochim. Pol. 46:721-726(1999).
RN   [80]
RP   VARIANTS HEMB.
RX   PubMed=10094553;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:2<160::AID-HUMU9>3.0.CO;2-C;
RA   Montejo J.M., Magallon M., Tizzano E., Solera J.;
RT   "Identification of twenty-one new mutations in the factor IX gene by
RT   SSCP analysis.";
RL   Hum. Mutat. 13:160-165(1999).
RN   [81]
RP   VARIANT ALA-194.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [82]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [83]
RP   VARIANTS HEMB CYS-169 AND THR-333.
RX   PubMed=11122099; DOI=10.1046/j.1365-2141.2000.02389.x;
RA   Vidal F., Farssac E., Altisent C., Puig L., Gallardo D.;
RT   "Factor IX gene sequencing by a simple and sensitive 15-hour procedure
RT   for haemophilia B diagnosis: identification of two novel mutations.";
RL   Br. J. Haematol. 111:549-551(2000).
RN   [84]
RP   VARIANTS HEMB TYR-28; LEU-43; GLN-43; SER-52; ASP-106; LYS-124;
RP   TYR-134; GLN-226; GLY-226; TRP-226; LYS-241; TYR-252; GLN-294;
RP   PHE-316; ARG-318; GLY-379; ILE-383; PHE-383; ILE-395; PHE-396; ARG-407
RP   AND GLU-412.
RX   PubMed=12588353; DOI=10.1046/j.1365-2141.2003.04141.x;
RA   Onay U.V., Kavakli K., Kilinc Y., Gurgey A., Aktuglu G., Kemahli S.,
RA   Ozbek U., Caglayan S.H.;
RT   "Molecular pathology of haemophilia B in Turkish patients:
RT   identification of a large deletion and 33 independent point
RT   mutations.";
RL   Br. J. Haematol. 120:656-659(2003).
RN   [85]
RP   VARIANTS HEMB TRP-43; ARG-84; ARG-125; VAL-125; PHE-170; ARG-302;
RP   MET-342; LEU-344; LEU-395; THR-414; TYR-435; GLU-442 AND TRP-449.
RX   PubMed=12604421;
RA   Espinos C., Casana P., Haya S., Cid A.R., Aznar J.A.;
RT   "Molecular analyses in hemophilia B families: identification of six
RT   new mutations in the factor IX gene.";
RL   Haematologica 88:235-236(2003).
RN   [86]
RP   VARIANT THPH8 LEU-384, CHARACTERIZATION OF VARIANT THPH8 LEU-384,
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=19846852; DOI=10.1056/NEJMoa0904377;
RA   Simioni P., Tormene D., Tognin G., Gavasso S., Bulato C.,
RA   Iacobelli N.P., Finn J.D., Spiezia L., Radu C., Arruda V.R.;
RT   "X-linked thrombophilia with a mutant factor IX (factor IX Padua).";
RL   N. Engl. J. Med. 361:1671-1675(2009).
RN   [87]
RP   VARIANTS HEMB ALA-194 AND HIS-241.
RX   PubMed=25470321; DOI=10.1111/hae.12553;
RA   Saini S., Hamasaki-Katagiri N., Pandey G.S., Yanover C., Guelcher C.,
RA   Simhadri V.L., Dandekar S., Guerrera M.F., Kimchi-Sarfaty C.,
RA   Sauna Z.E.;
RT   "Genetic determinants of immunogenicity to factor IX during the
RT   treatment of haemophilia B.";
RL   Haemophilia 21:210-218(2015).
CC   -!- FUNCTION: Factor IX is a vitamin K-dependent plasma protein that
CC       participates in the intrinsic pathway of blood coagulation by
CC       converting factor X to its active form in the presence of Ca(2+)
CC       ions, phospholipids, and factor VIIIa.
CC       {ECO:0000269|PubMed:1730085, ECO:0000269|PubMed:19846852,
CC       ECO:0000269|PubMed:20121197, ECO:0000269|PubMed:20121198,
CC       ECO:0000269|PubMed:2592373, ECO:0000269|PubMed:8295821}.
CC   -!- CATALYTIC ACTIVITY: Selective cleavage of Arg-|-Ile bond in factor
CC       X to form factor Xa. {ECO:0000269|PubMed:12444082,
CC       ECO:0000269|PubMed:20121197, ECO:0000269|PubMed:20121198,
CC       ECO:0000269|PubMed:2592373}.
CC   -!- SUBUNIT: Heterodimer of a light chain and a heavy chain;
CC       disulfide-linked (PubMed:20121198, PubMed:20121197,
CC       PubMed:20080729). Interacts with SERPINC1.
CC       {ECO:0000269|PubMed:20004170, ECO:0000269|PubMed:20080729,
CC       ECO:0000269|PubMed:20121197, ECO:0000269|PubMed:20121198,
CC       ECO:0000269|PubMed:2592373}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:19846852,
CC       ECO:0000269|PubMed:2592373, ECO:0000269|PubMed:3857619,
CC       ECO:0000269|PubMed:8295821, ECO:0000269|PubMed:9169594}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P00740-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P00740-2; Sequence=VSP_047689;
CC   -!- TISSUE SPECIFICITY: Detected in blood plasma (at protein level)
CC       (PubMed:3857619, PubMed:8295821, PubMed:2592373, PubMed:9169594,
CC       PubMed:19846852). Synthesized primarily in the liver and secreted
CC       in plasma. {ECO:0000269|PubMed:19846852,
CC       ECO:0000269|PubMed:2592373, ECO:0000269|PubMed:3857619}.
CC   -!- DOMAIN: Calcium binds to the gamma-carboxyglutamic acid (Gla)
CC       residues in the Gla domain. Calcium can also bind, with stronger
CC       affinity, to another site beyond the Gla domain (PubMed:6425296).
CC       Under physiological ion concentrations, Ca(2+) is displaced by
CC       Mg(2+) from some of the gammaglutamate residues in the N-terminal
CC       Gla domain. This leads to a subtle conformation change that may
CC       affect the interaction with its binding protein (By similarity).
CC       {ECO:0000250|UniProtKB:P00741, ECO:0000269|PubMed:14722079,
CC       ECO:0000269|PubMed:1730085, ECO:0000269|PubMed:6425296}.
CC   -!- PTM: Activated by factor XIa, which excises the activation peptide
CC       (PubMed:9169594, PubMed:1730085). The propeptide can also be
CC       removed by snake venom protease (PubMed:20004170,
CC       PubMed:20080729). {ECO:0000269|PubMed:1730085,
CC       ECO:0000269|PubMed:20004170, ECO:0000269|PubMed:20080729,
CC       ECO:0000269|PubMed:2592373, ECO:0000269|PubMed:8295821,
CC       ECO:0000269|PubMed:9169594}.
CC   -!- PTM: The iron and 2-oxoglutarate dependent 3-hydroxylation of
CC       aspartate and asparagine is (R) stereospecific within EGF domains.
CC       {ECO:0000269|PubMed:6688526}.
CC   -!- PTM: Predominantly O-glucosylated at Ser-99 by POGLUT1 in vitro.
CC       Xylosylation at this site is minor.
CC   -!- DISEASE: Hemophilia B (HEMB) [MIM:306900]: An X-linked blood
CC       coagulation disorder characterized by a permanent tendency to
CC       hemorrhage, due to factor IX deficiency. It is phenotypically
CC       similar to hemophilia A, but patients present with fewer symptoms.
CC       Many patients are asymptomatic until the hemostatic system is
CC       stressed by surgery or trauma. {ECO:0000269|PubMed:10094553,
CC       ECO:0000269|PubMed:10698280, ECO:0000269|PubMed:11122099,
CC       ECO:0000269|PubMed:12588353, ECO:0000269|PubMed:12604421,
CC       ECO:0000269|PubMed:1346975, ECO:0000269|PubMed:1615485,
CC       ECO:0000269|PubMed:1902289, ECO:0000269|PubMed:1958666,
CC       ECO:0000269|PubMed:2162822, ECO:0000269|PubMed:2339358,
CC       ECO:0000269|PubMed:2372509, ECO:0000269|PubMed:2472424,
CC       ECO:0000269|PubMed:25470321, ECO:0000269|PubMed:2592373,
CC       ECO:0000269|PubMed:2713493, ECO:0000269|PubMed:2714791,
CC       ECO:0000269|PubMed:2738071, ECO:0000269|PubMed:2753873,
CC       ECO:0000269|PubMed:2773937, ECO:0000269|PubMed:2775660,
CC       ECO:0000269|PubMed:3009023, ECO:0000269|PubMed:3243764,
CC       ECO:0000269|PubMed:3401602, ECO:0000269|PubMed:3790720,
CC       ECO:0000269|PubMed:6603618, ECO:0000269|PubMed:7981722,
CC       ECO:0000269|PubMed:8076946, ECO:0000269|PubMed:8199596,
CC       ECO:0000269|PubMed:8257988, ECO:0000269|PubMed:8295821,
CC       ECO:0000269|PubMed:8680410, ECO:0000269|PubMed:9222764,
CC       ECO:0000269|PubMed:9452115, ECO:0000269|PubMed:9590153,
CC       ECO:0000269|PubMed:9600455}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Mutations in position 43 (Oxford-3, San Dimas) and
CC       46 (Cambridge) prevents cleavage of the propeptide, mutation in
CC       position 93 (Alabama) probably fails to bind to cell membranes,
CC       mutation in position 191 (Chapel-Hill) or in position 226 (Nagoya
CC       OR Hilo) prevent cleavage of the activation peptide.
CC   -!- DISEASE: Thrombophilia, X-linked, due to factor IX defect (THPH8)
CC       [MIM:300807]: A hemostatic disorder characterized by a tendency to
CC       thrombosis. {ECO:0000269|PubMed:19846852}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- PHARMACEUTICAL: Available under the name BeneFix (Baxter and
CC       American Home Products). Used to treat hemophilia B.
CC   -!- MISCELLANEOUS: In 1952, one of the earliest researchers of the
CC       disease, Dr. R.G. Macfarlane used the patient's surname,
CC       Christmas, to refer to the disease and also to refer to the
CC       clotting factor which he called the 'Christmas Factor' At the time
CC       Stephen Christmas was a 5-year-old boy. He died in 1993 at the age
CC       of 46 from acquired immunodeficiency syndrome contracted through
CC       treatment with blood products.
CC   -!- SIMILARITY: Belongs to the peptidase S1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00274}.
CC   -!- SIMILARITY: Contains 2 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 1 Gla (gamma-carboxy-glutamate) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00463}.
CC   -!- SIMILARITY: Contains 1 peptidase S1 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00274}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Factor IX entry;
CC       URL="http://en.wikipedia.org/wiki/Factor_IX";
CC   -!- WEB RESOURCE: Name=Factor IX Mutation Database;
CC       URL="http://www.factorix.org/";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/f9/";
CC   -!- WEB RESOURCE: Name=BeneFix; Note=Clinical information on BeneFix;
CC       URL="http://www.pfizer.com/products/rx/rx_product_benefix.jsp";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=The Christmas Factor -
CC       Issue 41 of December 2003;
CC       URL="http://web.expasy.org/spotlight/back_issues/041";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J00136; AAA98726.1; -; mRNA.
DR   EMBL; J00137; AAA52763.1; -; mRNA.
DR   EMBL; K02053; AAA56822.1; -; Genomic_DNA.
DR   EMBL; K02048; AAA56822.1; JOINED; Genomic_DNA.
DR   EMBL; K02049; AAA56822.1; JOINED; Genomic_DNA.
DR   EMBL; K02051; AAA56822.1; JOINED; Genomic_DNA.
DR   EMBL; K02052; AAA56822.1; JOINED; Genomic_DNA.
DR   EMBL; K02402; AAB59620.1; -; Genomic_DNA.
DR   EMBL; M11309; AAA52023.1; -; mRNA.
DR   EMBL; AL033403; CAI42103.1; -; Genomic_DNA.
DR   EMBL; AB186358; BAD89383.1; -; mRNA.
DR   EMBL; AF536327; AAM96188.1; -; Genomic_DNA.
DR   EMBL; FR846239; CCA61111.1; -; mRNA.
DR   EMBL; AK292749; BAF85438.1; -; mRNA.
DR   EMBL; CH471150; EAW88433.1; -; Genomic_DNA.
DR   EMBL; BC109214; AAI09215.1; -; mRNA.
DR   EMBL; BC109215; AAI09216.1; -; mRNA.
DR   EMBL; S68634; AAB29758.1; -; Genomic_DNA.
DR   EMBL; M35672; AAA51981.1; -; mRNA.
DR   EMBL; M19063; AAA52456.1; -; Genomic_DNA.
DR   EMBL; S66752; AAB28588.1; -; Genomic_DNA.
DR   CCDS; CCDS14666.1; -. [P00740-1]
DR   PIR; A00922; KFHU.
DR   RefSeq; NP_000124.1; NM_000133.3. [P00740-1]
DR   UniGene; Hs.522798; -.
DR   PDB; 1CFH; NMR; -; A=47-93.
DR   PDB; 1CFI; NMR; -; A=47-93.
DR   PDB; 1EDM; X-ray; 1.50 A; B/C=92-130.
DR   PDB; 1IXA; NMR; -; A=92-130.
DR   PDB; 1MGX; NMR; -; A=47-93.
DR   PDB; 1NL0; X-ray; 2.20 A; G=47-91.
DR   PDB; 1RFN; X-ray; 2.80 A; A=227-461, B=133-188.
DR   PDB; 2WPH; X-ray; 1.50 A; E=133-191, S=227-461.
DR   PDB; 2WPI; X-ray; 1.99 A; E=133-191, S=227-461.
DR   PDB; 2WPJ; X-ray; 1.60 A; E=133-191, S=227-461.
DR   PDB; 2WPK; X-ray; 2.21 A; E=133-191, S=227-461.
DR   PDB; 2WPL; X-ray; 1.82 A; E=133-191, S=227-461.
DR   PDB; 2WPM; X-ray; 2.00 A; E=133-191, S=227-461.
DR   PDB; 3KCG; X-ray; 1.70 A; H=227-461, L=131-188.
DR   PDB; 3LC3; X-ray; 1.90 A; A/C=227-461, B/D=133-188.
DR   PDB; 3LC5; X-ray; 2.62 A; A=227-461, B=133-188.
DR   PDB; 4YZU; X-ray; 1.41 A; A=227-461, B=131-191.
DR   PDB; 4Z0K; X-ray; 1.41 A; A=227-461, B=131-191.
DR   PDB; 4ZAE; X-ray; 1.86 A; A=227-461, B=131-191.
DR   PDBsum; 1CFH; -.
DR   PDBsum; 1CFI; -.
DR   PDBsum; 1EDM; -.
DR   PDBsum; 1IXA; -.
DR   PDBsum; 1MGX; -.
DR   PDBsum; 1NL0; -.
DR   PDBsum; 1RFN; -.
DR   PDBsum; 2WPH; -.
DR   PDBsum; 2WPI; -.
DR   PDBsum; 2WPJ; -.
DR   PDBsum; 2WPK; -.
DR   PDBsum; 2WPL; -.
DR   PDBsum; 2WPM; -.
DR   PDBsum; 3KCG; -.
DR   PDBsum; 3LC3; -.
DR   PDBsum; 3LC5; -.
DR   PDBsum; 4YZU; -.
DR   PDBsum; 4Z0K; -.
DR   PDBsum; 4ZAE; -.
DR   ProteinModelPortal; P00740; -.
DR   SMR; P00740; 47-191, 227-461.
DR   BioGrid; 108456; 10.
DR   DIP; DIP-58520N; -.
DR   IntAct; P00740; 1.
DR   STRING; 9606.ENSP00000218099; -.
DR   BindingDB; P00740; -.
DR   ChEMBL; CHEMBL2016; -.
DR   DrugBank; DB00025; Antihemophilic Factor.
DR   DrugBank; DB00170; Menadione.
DR   GuidetoPHARMACOLOGY; 2364; -.
DR   Allergome; 9616; Hom s Factor IX.
DR   MEROPS; S01.214; -.
DR   PhosphoSite; P00740; -.
DR   UniCarbKB; P00740; -.
DR   BioMuta; F9; -.
DR   PaxDb; P00740; -.
DR   PeptideAtlas; P00740; -.
DR   PRIDE; P00740; -.
DR   DNASU; 2158; -.
DR   Ensembl; ENST00000218099; ENSP00000218099; ENSG00000101981.
DR   Ensembl; ENST00000394090; ENSP00000377650; ENSG00000101981. [P00740-2]
DR   GeneID; 2158; -.
DR   KEGG; hsa:2158; -.
DR   UCSC; uc004fas.1; human. [P00740-1]
DR   CTD; 2158; -.
DR   GeneCards; GC0XP138612; -.
DR   GeneReviews; F9; -.
DR   HGNC; HGNC:3551; F9.
DR   MIM; 300746; gene.
DR   MIM; 300807; phenotype.
DR   MIM; 306900; phenotype.
DR   neXtProt; NX_P00740; -.
DR   Orphanet; 169799; Mild hemophilia B.
DR   Orphanet; 169796; Moderately severe hemophilia B.
DR   Orphanet; 169793; Severe hemophilia B.
DR   Orphanet; 177929; Symptomatic form of hemophilia B in female carriers.
DR   PharmGKB; PA27954; -.
DR   eggNOG; COG5640; -.
DR   GeneTree; ENSGT00760000118890; -.
DR   HOGENOM; HOG000251821; -.
DR   HOVERGEN; HBG013304; -.
DR   InParanoid; P00740; -.
DR   KO; K01321; -.
DR   OMA; MKGKYGI; -.
DR   OrthoDB; EOG75B84T; -.
DR   PhylomeDB; P00740; -.
DR   TreeFam; TF327329; -.
DR   BRENDA; 3.4.21.22; 2681.
DR   Reactome; REACT_1050; Gamma-carboxylation of protein precursors.
DR   Reactome; REACT_1573; Extrinsic Pathway of Fibrin Clot Formation.
DR   Reactome; REACT_1906; Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus.
DR   Reactome; REACT_326; Intrinsic Pathway of Fibrin Clot Formation.
DR   Reactome; REACT_733; Removal of aminoterminal propeptides from gamma-carboxylated proteins.
DR   SABIO-RK; P00740; -.
DR   EvolutionaryTrace; P00740; -.
DR   GeneWiki; Factor_IX; -.
DR   GenomeRNAi; 2158; -.
DR   NextBio; 8719; -.
DR   PMAP-CutDB; P00740; -.
DR   PRO; PR:P00740; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; P00740; -.
DR   CleanEx; HS_F9; -.
DR   Genevisible; P00740; HS.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0004175; F:endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; TAS:ProtInc.
DR   GO; GO:0007596; P:blood coagulation; IDA:UniProtKB.
DR   GO; GO:0007598; P:blood coagulation, extrinsic pathway; TAS:Reactome.
DR   GO; GO:0007597; P:blood coagulation, intrinsic pathway; TAS:Reactome.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0017187; P:peptidyl-glutamic acid carboxylation; TAS:Reactome.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0006508; P:proteolysis; IDA:UniProtKB.
DR   GO; GO:0031638; P:zymogen activation; IDA:UniProtKB.
DR   Gene3D; 4.10.740.10; -; 1.
DR   InterPro; IPR017857; Coagulation_fac_subgr_Gla_dom.
DR   InterPro; IPR000742; EG-like_dom.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR000294; GLA_domain.
DR   InterPro; IPR012224; Pept_S1A_FX.
DR   InterPro; IPR001254; Peptidase_S1.
DR   InterPro; IPR018114; Peptidase_S1_AS.
DR   InterPro; IPR001314; Peptidase_S1A.
DR   InterPro; IPR009003; Trypsin-like_Pept_dom.
DR   Pfam; PF00008; EGF; 1.
DR   Pfam; PF00594; Gla; 1.
DR   Pfam; PF00089; Trypsin; 1.
DR   PIRSF; PIRSF001143; Factor_X; 1.
DR   PRINTS; PR00722; CHYMOTRYPSIN.
DR   PRINTS; PR00001; GLABLOOD.
DR   SMART; SM00181; EGF; 1.
DR   SMART; SM00179; EGF_CA; 1.
DR   SMART; SM00069; GLA; 1.
DR   SMART; SM00020; Tryp_SPc; 1.
DR   SUPFAM; SSF50494; SSF50494; 1.
DR   SUPFAM; SSF57630; SSF57630; 1.
DR   PROSITE; PS00010; ASX_HYDROXYL; 1.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 2.
DR   PROSITE; PS50026; EGF_3; 1.
DR   PROSITE; PS01187; EGF_CA; 1.
DR   PROSITE; PS00011; GLA_1; 1.
DR   PROSITE; PS50998; GLA_2; 1.
DR   PROSITE; PS50240; TRYPSIN_DOM; 1.
DR   PROSITE; PS00134; TRYPSIN_HIS; 1.
DR   PROSITE; PS00135; TRYPSIN_SER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Blood coagulation; Calcium;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   EGF-like domain; Gamma-carboxyglutamic acid; Glycoprotein; Hemophilia;
KW   Hemostasis; Hydrolase; Hydroxylation; Magnesium; Metal-binding;
KW   Pharmaceutical; Phosphoprotein; Polymorphism; Protease;
KW   Reference proteome; Repeat; Secreted; Serine protease; Signal;
KW   Sulfation; Thrombophilia; Zymogen.
FT   SIGNAL        1     28       {ECO:0000255}.
FT   PROPEP       29     46       {ECO:0000269|PubMed:2592373}.
FT                                /FTId=PRO_0000027755.
FT   CHAIN        47    461       Coagulation factor IX.
FT                                /FTId=PRO_0000027756.
FT   CHAIN        47    191       Coagulation factor IXa light chain.
FT                                /FTId=PRO_0000027757.
FT   PROPEP      192    226       Activation peptide.
FT                                /FTId=PRO_0000027758.
FT   CHAIN       227    461       Coagulation factor IXa heavy chain.
FT                                /FTId=PRO_0000027759.
FT   DOMAIN       47     92       Gla. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463}.
FT   DOMAIN       93    129       EGF-like 1; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      130    171       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      227    459       Peptidase S1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00274}.
FT   ACT_SITE    267    267       Charge relay system.
FT                                {ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:659613}.
FT   ACT_SITE    315    315       Charge relay system.
FT                                {ECO:0000269|PubMed:659613}.
FT   ACT_SITE    411    411       Charge relay system.
FT                                {ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:659613}.
FT   METAL        47     47       Calcium 1; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000269|PubMed:14722079}.
FT   METAL        48     48       Calcium 2. {ECO:0000244|PDB:1NL0,
FT                                ECO:0000269|PubMed:14722079}.
FT   METAL        53     53       Calcium 1; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        53     53       Calcium 2; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        54     54       Calcium 2; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        54     54       Calcium 3; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        61     61       Calcium 4 or magnesium 1; via 4-
FT                                carboxyglutamate. {ECO:0000244|PDB:1NL0,
FT                                ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        63     63       Calcium 1; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        63     63       Calcium 2; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        63     63       Calcium 3; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        66     66       Calcium 4 or magnesium 1; via 4-
FT                                carboxyglutamate. {ECO:0000244|PDB:1NL0,
FT                                ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        67     67       Calcium 1; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        72     72       Calcium 5 or magnesium 2; via 4-
FT                                carboxyglutamate. {ECO:0000244|PDB:1NL0,
FT                                ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        73     73       Calcium 2; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        73     73       Calcium 3; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        76     76       Calcium 3; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        76     76       Calcium 5 or magnesium 2; via 4-
FT                                carboxyglutamate. {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        76     76       Calcium 5; via 4-carboxyglutamate.
FT                                {ECO:0000244|PDB:1NL0,
FT                                ECO:0000305|PubMed:14722079}.
FT   METAL        82     82       Calcium 6 or magnesium 3; via 4-
FT                                carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741}.
FT   METAL        86     86       Calcium 6 or magnesium 3; via 4-
FT                                carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741}.
FT   METAL        93     93       Calcium 7. {ECO:0000244|PDB:1EDM,
FT                                ECO:0000269|PubMed:7606779}.
FT   METAL        94     94       Calcium 7; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1EDM,
FT                                ECO:0000269|PubMed:7606779}.
FT   METAL        96     96       Calcium 7. {ECO:0000244|PDB:1EDM,
FT                                ECO:0000269|PubMed:7606779}.
FT   METAL       110    110       Calcium 7. {ECO:0000244|PDB:1EDM,
FT                                ECO:0000269|PubMed:7606779}.
FT   METAL       111    111       Calcium 7; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1EDM,
FT                                ECO:0000269|PubMed:7606779}.
FT   METAL       281    281       Calcium 8. {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:10467148,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   METAL       283    283       Calcium 8; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:10467148,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   METAL       286    286       Calcium 8; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:10467148,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   METAL       288    288       Calcium 8. {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:10467148,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   METAL       291    291       Calcium 8. {ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:10467148,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   SITE        191    192       Cleavage; by factor XIa.
FT   SITE        226    227       Cleavage; by factor XIa.
FT   MOD_RES      53     53       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      54     54       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      61     61       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      63     63       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      66     66       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      67     67       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      72     72       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      73     73       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      76     76       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      79     79       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      82     82       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES      86     86       4-carboxyglutamate.
FT                                {ECO:0000250|UniProtKB:P00741,
FT                                ECO:0000255|PROSITE-ProRule:PRU00463}.
FT   MOD_RES     110    110       (3R)-3-hydroxyaspartate.
FT                                {ECO:0000269|PubMed:6688526}.
FT   MOD_RES     114    114       Phosphoserine. {ECO:0000269|Ref.28}.
FT   MOD_RES     201    201       Sulfotyrosine.
FT                                {ECO:0000269|PubMed:11133752}.
FT   MOD_RES     204    204       Phosphoserine.
FT                                {ECO:0000269|PubMed:11133752,
FT                                ECO:0000269|PubMed:25456591}.
FT   MOD_RES     205    205       Phosphothreonine.
FT                                {ECO:0000269|PubMed:25456591}.
FT   CARBOHYD     85     85       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:25456591}.
FT   CARBOHYD     99     99       O-linked (Glc...); alternate.
FT                                {ECO:0000269|PubMed:21949356,
FT                                ECO:0000269|PubMed:25456591}.
FT                                /FTId=CAR_000009.
FT   CARBOHYD     99     99       O-linked (Xyl...); alternate.
FT                                {ECO:0000269|PubMed:21949356}.
FT   CARBOHYD    107    107       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:25456591}.
FT                                /FTId=CAR_000010.
FT   CARBOHYD    203    203       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    205    205       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:25456591,
FT                                ECO:0000269|PubMed:8172892}.
FT   CARBOHYD    213    213       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    215    215       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:25456591,
FT                                ECO:0000269|PubMed:8172892}.
FT   CARBOHYD    225    225       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:25456591}.
FT   DISULFID     64     69       {ECO:0000250|UniProtKB:P00741}.
FT   DISULFID     97    108       {ECO:0000244|PDB:1EDM,
FT                                ECO:0000244|PDB:1IXA,
FT                                ECO:0000269|PubMed:1304885,
FT                                ECO:0000269|PubMed:7606779}.
FT   DISULFID    102    117       {ECO:0000244|PDB:1EDM,
FT                                ECO:0000244|PDB:1IXA,
FT                                ECO:0000269|PubMed:1304885,
FT                                ECO:0000269|PubMed:7606779}.
FT   DISULFID    119    128       {ECO:0000244|PDB:1EDM,
FT                                ECO:0000244|PDB:1IXA,
FT                                ECO:0000269|PubMed:1304885,
FT                                ECO:0000269|PubMed:7606779}.
FT   DISULFID    134    145       {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPL,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   DISULFID    141    155       {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPL,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   DISULFID    157    170       {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPL,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   DISULFID    178    335       Interchain (between light and heavy
FT                                chains). {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPL,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   DISULFID    252    268       {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPL,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   DISULFID    382    396       {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPL,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   DISULFID    407    435       {ECO:0000244|PDB:1RFN,
FT                                ECO:0000244|PDB:2WPH,
FT                                ECO:0000244|PDB:2WPI,
FT                                ECO:0000244|PDB:2WPJ,
FT                                ECO:0000244|PDB:2WPK,
FT                                ECO:0000244|PDB:2WPL,
FT                                ECO:0000244|PDB:2WPM,
FT                                ECO:0000244|PDB:3KCG,
FT                                ECO:0000244|PDB:3LC3,
FT                                ECO:0000244|PDB:3LC5,
FT                                ECO:0000269|PubMed:20004170,
FT                                ECO:0000269|PubMed:20080729,
FT                                ECO:0000269|PubMed:20121197,
FT                                ECO:0000269|PubMed:20121198}.
FT   VAR_SEQ      93    130       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.6}.
FT                                /FTId=VSP_047689.
FT   VARIANT       7      7       I -> F (in dbSNP:rs150190385).
FT                                {ECO:0000269|PubMed:2773937}.
FT                                /FTId=VAR_006520.
FT   VARIANT      17     17       I -> N (in HEMB; severe; UK 22).
FT                                /FTId=VAR_006521.
FT   VARIANT      28     28       C -> R (in HEMB; moderate; HB130).
FT                                /FTId=VAR_006522.
FT   VARIANT      28     28       C -> Y (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017343.
FT   VARIANT      30     30       V -> I (in HEMB).
FT                                /FTId=VAR_006523.
FT   VARIANT      37     37       A -> T (in warfarin sensitivity; reduced
FT                                affinity of the glutamate carboxylase for
FT                                the factor IX precursor).
FT                                {ECO:0000269|PubMed:8833911}.
FT                                /FTId=VAR_017307.
FT   VARIANT      43     43       R -> L (in HEMB; severe; Bendorf, Beuten,
FT                                Gleiwitz; impairs removal of propeptide).
FT                                {ECO:0000269|PubMed:12588353,
FT                                ECO:0000269|PubMed:9169594}.
FT                                /FTId=VAR_006525.
FT   VARIANT      43     43       R -> Q (in HEMB; severe; San Dimas,
FT                                Oxford-3, Strasbourg-2; impairs removal
FT                                of propeptide).
FT                                {ECO:0000269|PubMed:12588353,
FT                                ECO:0000269|PubMed:2738071,
FT                                ECO:0000269|PubMed:3009023,
FT                                ECO:0000269|PubMed:8295821,
FT                                ECO:0000269|PubMed:9169594,
FT                                ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006524.
FT   VARIANT      43     43       R -> W (in HEMB; severe; Boxtel, Heiden,
FT                                Lienen; impairs removal of propeptide).
FT                                {ECO:0000269|PubMed:12604421,
FT                                ECO:0000269|PubMed:9169594,
FT                                ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006526.
FT   VARIANT      45     45       K -> N (in HEMB; severe; Seattle E).
FT                                /FTId=VAR_006527.
FT   VARIANT      46     46       R -> S (in HEMB; severe; Cambridge).
FT                                /FTId=VAR_006528.
FT   VARIANT      46     46       R -> T (in HEMB; severe).
FT                                {ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006529.
FT   VARIANT      48     48       N -> I (in HEMB; severe; Calgary-16).
FT                                /FTId=VAR_006530.
FT   VARIANT      49     49       S -> P (in HEMB).
FT                                /FTId=VAR_006531.
FT   VARIANT      52     52       L -> S (in HEMB; severe; Gla mutant).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017344.
FT   VARIANT      53     53       E -> A (in HEMB; severe; Oxford-B2; Gla
FT                                mutant).
FT                                /FTId=VAR_006532.
FT   VARIANT      54     54       E -> G (in HEMB; severe; HB151; Gla
FT                                mutant).
FT                                /FTId=VAR_006533.
FT   VARIANT      55     55       F -> C (in HEMB).
FT                                /FTId=VAR_006534.
FT   VARIANT      58     58       G -> A (in HEMB; severe; Hong Kong-1).
FT                                /FTId=VAR_006535.
FT   VARIANT      58     58       G -> R (in HEMB; severe; Los Angeles-4).
FT                                /FTId=VAR_006536.
FT   VARIANT      62     63       Missing (in HEMB; severe).
FT                                /FTId=VAR_006537.
FT   VARIANT      66     66       E -> V (in HEMB; moderate).
FT                                /FTId=VAR_006538.
FT   VARIANT      67     67       E -> K (in HEMB; severe; Nagoya-4; Gla
FT                                mutant).
FT                                /FTId=VAR_006539.
FT   VARIANT      71     71       F -> S (in HEMB; severe).
FT                                /FTId=VAR_006540.
FT   VARIANT      73     73       E -> K (in HEMB; severe; Seattle-3; Gla
FT                                mutant). {ECO:0000269|PubMed:2472424}.
FT                                /FTId=VAR_006541.
FT   VARIANT      73     73       E -> V (in HEMB; severe; Chongqing; Gla
FT                                mutant). {ECO:0000269|PubMed:2339358}.
FT                                /FTId=VAR_006542.
FT   VARIANT      75     75       R -> Q (in HEMB; mild).
FT                                {ECO:0000269|PubMed:2773937}.
FT                                /FTId=VAR_017308.
FT   VARIANT      79     79       E -> D (in HEMB).
FT                                {ECO:0000269|PubMed:2773937}.
FT                                /FTId=VAR_017309.
FT   VARIANT      84     84       T -> R (in HEMB).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_017345.
FT   VARIANT      91     91       Y -> C (in HEMB; moderate).
FT                                /FTId=VAR_006543.
FT   VARIANT      93     93       D -> G (in HEMB; moderate; Alabama).
FT                                {ECO:0000269|PubMed:3790720}.
FT                                /FTId=VAR_006544.
FT   VARIANT      96     96       Q -> P (in HEMB; severe; New London).
FT                                /FTId=VAR_006545.
FT   VARIANT      97     97       C -> S (in HEMB).
FT                                /FTId=VAR_006546.
FT   VARIANT     101    101       P -> R (in HEMB).
FT                                /FTId=VAR_006547.
FT   VARIANT     102    102       C -> R (in HEMB; severe; Basel).
FT                                /FTId=VAR_006548.
FT   VARIANT     106    106       G -> D (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017346.
FT   VARIANT     106    106       G -> S (in HEMB; mild; Durham).
FT                                {ECO:0000269|PubMed:2472424,
FT                                ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006549.
FT   VARIANT     108    108       C -> S (in HEMB).
FT                                /FTId=VAR_006550.
FT   VARIANT     110    110       D -> N (in HEMB; severe; Oxford-D1).
FT                                /FTId=VAR_006551.
FT   VARIANT     112    112       I -> S (in HEMB).
FT                                /FTId=VAR_006552.
FT   VARIANT     113    113       N -> K (in HEMB; mild).
FT                                {ECO:0000269|PubMed:9222764}.
FT                                /FTId=VAR_006553.
FT   VARIANT     115    115       Y -> C (in HEMB; severe).
FT                                {ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006554.
FT   VARIANT     119    119       C -> F (in HEMB; severe).
FT                                /FTId=VAR_006555.
FT   VARIANT     119    119       C -> R (in HEMB; Iran).
FT                                {ECO:0000269|PubMed:9452115}.
FT                                /FTId=VAR_006556.
FT   VARIANT     124    124       E -> K (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017347.
FT   VARIANT     125    125       G -> E (in HEMB).
FT                                /FTId=VAR_006557.
FT   VARIANT     125    125       G -> R (in HEMB).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_017348.
FT   VARIANT     125    125       G -> V (in HEMB).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_006558.
FT   VARIANT     129    130       Missing (in HEMB).
FT                                /FTId=VAR_006559.
FT   VARIANT     134    134       C -> Y (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017349.
FT   VARIANT     136    136       I -> T (in HEMB; mild).
FT                                /FTId=VAR_006560.
FT   VARIANT     139    139       G -> D (in HEMB; severe).
FT                                /FTId=VAR_006561.
FT   VARIANT     139    139       G -> S (in HEMB).
FT                                /FTId=VAR_006562.
FT   VARIANT     155    155       C -> F (in HEMB; severe).
FT                                {ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006563.
FT   VARIANT     160    160       G -> E (in HEMB; mild).
FT                                /FTId=VAR_006564.
FT   VARIANT     167    167       Q -> H (in HEMB; mild).
FT                                /FTId=VAR_006565.
FT   VARIANT     169    169       S -> C (in HEMB).
FT                                {ECO:0000269|PubMed:11122099}.
FT                                /FTId=VAR_017350.
FT   VARIANT     170    170       C -> F (in HEMB).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_017351.
FT   VARIANT     178    178       C -> R (in HEMB).
FT                                /FTId=VAR_006566.
FT   VARIANT     178    178       C -> W (in HEMB; severe).
FT                                /FTId=VAR_006567.
FT   VARIANT     191    191       R -> C (in HEMB; moderate; Albuquerque,
FT                                Cardiff-1). {ECO:0000269|PubMed:2775660}.
FT                                /FTId=VAR_006569.
FT   VARIANT     191    191       R -> H (in HEMB; moderate; Chapel-Hill,
FT                                Chicago-2). {ECO:0000269|PubMed:6603618,
FT                                ECO:0000269|PubMed:8076946}.
FT                                /FTId=VAR_006568.
FT   VARIANT     194    194       T -> A (in dbSNP:rs6048).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:25470321,
FT                                ECO:0000269|PubMed:2994716,
FT                                ECO:0000269|PubMed:3857619,
FT                                ECO:0000269|PubMed:6329734}.
FT                                /FTId=VAR_011773.
FT   VARIANT     226    226       R -> G (in HEMB; severe; Madrid).
FT                                {ECO:0000269|PubMed:12588353,
FT                                ECO:0000269|PubMed:8076946}.
FT                                /FTId=VAR_006571.
FT   VARIANT     226    226       R -> Q (in HEMB; severe; Hilo and
FT                                Novara). {ECO:0000269|PubMed:12588353,
FT                                ECO:0000269|PubMed:2162822,
FT                                ECO:0000269|PubMed:2713493}.
FT                                /FTId=VAR_006572.
FT   VARIANT     226    226       R -> W (in HEMB; severe; Nagoya-1,
FT                                Dernbach, Deventer, Idaho).
FT                                {ECO:0000269|PubMed:12588353,
FT                                ECO:0000269|PubMed:2162822,
FT                                ECO:0000269|PubMed:2592373}.
FT                                /FTId=VAR_006570.
FT   VARIANT     227    227       V -> D (in HEMB; mild).
FT                                /FTId=VAR_006573.
FT   VARIANT     227    227       V -> F (in HEMB; Milano).
FT                                {ECO:0000269|PubMed:2162822}.
FT                                /FTId=VAR_017310.
FT   VARIANT     228    228       V -> F (in HEMB; severe; Kashihara).
FT                                {ECO:0000269|PubMed:2753873}.
FT                                /FTId=VAR_017311.
FT   VARIANT     228    228       V -> L (in HEMB; mild; Cardiff-2).
FT                                {ECO:0000269|PubMed:2372509}.
FT                                /FTId=VAR_006574.
FT   VARIANT     241    241       Q -> H (in HEMB).
FT                                {ECO:0000269|PubMed:25470321}.
FT                                /FTId=VAR_006575.
FT   VARIANT     241    241       Q -> K (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017352.
FT   VARIANT     252    252       C -> S (in HEMB; severe).
FT                                {ECO:0000269|PubMed:1615485}.
FT                                /FTId=VAR_017312.
FT   VARIANT     252    252       C -> Y (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017353.
FT   VARIANT     253    253       G -> E (in HEMB; severe).
FT                                /FTId=VAR_006576.
FT   VARIANT     253    253       G -> R (in HEMB; severe; Luanda).
FT                                {ECO:0000269|PubMed:8257988}.
FT                                /FTId=VAR_006577.
FT   VARIANT     265    265       A -> T (in HEMB; mild).
FT                                /FTId=VAR_006578.
FT   VARIANT     268    268       C -> W (in HEMB; moderate).
FT                                {ECO:0000269|PubMed:2773937}.
FT                                /FTId=VAR_017313.
FT   VARIANT     279    279       A -> T (in HEMB; mild).
FT                                {ECO:0000269|PubMed:2773937,
FT                                ECO:0000269|PubMed:8076946}.
FT                                /FTId=VAR_006579.
FT   VARIANT     283    283       N -> D (in HEMB; severe).
FT                                /FTId=VAR_006580.
FT   VARIANT     286    286       Missing (in HEMB; severe).
FT                                /FTId=VAR_006581.
FT   VARIANT     291    291       E -> V (in HEMB; Monschau).
FT                                {ECO:0000269|PubMed:1346975}.
FT                                /FTId=VAR_017314.
FT   VARIANT     294    294       R -> G (in HEMB; severe).
FT                                /FTId=VAR_006582.
FT   VARIANT     294    294       R -> Q (in HEMB; mild to moderate;
FT                                Dreihacken, Penafiel and Seattle-4).
FT                                {ECO:0000269|PubMed:12588353,
FT                                ECO:0000269|PubMed:1346975,
FT                                ECO:0000269|PubMed:2472424,
FT                                ECO:0000269|PubMed:7981722,
FT                                ECO:0000269|PubMed:8257988}.
FT                                /FTId=VAR_006583.
FT   VARIANT     302    302       H -> R (in HEMB).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_006584.
FT   VARIANT     306    306       N -> S (in HEMB; mild).
FT                                {ECO:0000269|PubMed:2773937}.
FT                                /FTId=VAR_017315.
FT   VARIANT     316    316       I -> F (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_006585.
FT   VARIANT     318    318       L -> R (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017354.
FT   VARIANT     321    321       L -> Q (in HEMB; severe).
FT                                /FTId=VAR_006586.
FT   VARIANT     333    333       P -> H (in HEMB; severe).
FT                                /FTId=VAR_006587.
FT   VARIANT     333    333       P -> T (in HEMB).
FT                                {ECO:0000269|PubMed:11122099}.
FT                                /FTId=VAR_017355.
FT   VARIANT     342    342       T -> K (in HEMB; mild).
FT                                /FTId=VAR_006588.
FT   VARIANT     342    342       T -> M (in HEMB; moderate).
FT                                {ECO:0000269|PubMed:12604421,
FT                                ECO:0000269|PubMed:2773937,
FT                                ECO:0000269|PubMed:9222764}.
FT                                /FTId=VAR_006589.
FT   VARIANT     344    344       I -> L (in HEMB).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_017356.
FT   VARIANT     351    351       G -> D (in HEMB).
FT                                /FTId=VAR_006590.
FT   VARIANT     356    356       W -> C (in HEMB; severe).
FT                                /FTId=VAR_006591.
FT   VARIANT     357    357       G -> E (in HEMB; severe; Amagasaki).
FT                                {ECO:0000269|PubMed:1958666}.
FT                                /FTId=VAR_006592.
FT   VARIANT     357    357       G -> R (in HEMB).
FT                                {ECO:0000269|PubMed:2773937}.
FT                                /FTId=VAR_017316.
FT   VARIANT     362    362       K -> E (in HEMB; moderate).
FT                                /FTId=VAR_006593.
FT   VARIANT     363    363       G -> W (in HEMB).
FT                                /FTId=VAR_006594.
FT   VARIANT     366    366       A -> D (in HEMB).
FT                                /FTId=VAR_006595.
FT   VARIANT     379    379       R -> G (in HEMB; moderate).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_006596.
FT   VARIANT     379    379       R -> Q (in HEMB; severe; Iceland-1,
FT                                London and Sesimbra).
FT                                {ECO:0000269|PubMed:8076946,
FT                                ECO:0000269|PubMed:8257988,
FT                                ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006597.
FT   VARIANT     382    382       C -> Y (in HEMB).
FT                                /FTId=VAR_006598.
FT   VARIANT     383    383       L -> F (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017358.
FT   VARIANT     383    383       L -> I (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017357.
FT   VARIANT     384    384       R -> L (in THPH8; factor IX Padua; higher
FT                                specific activity than wild-type).
FT                                {ECO:0000269|PubMed:19846852}.
FT                                /FTId=VAR_062999.
FT   VARIANT     387    387       K -> E (in HEMB; mild).
FT                                {ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006599.
FT   VARIANT     390    390       I -> F (in HEMB; severe).
FT                                /FTId=VAR_006600.
FT   VARIANT     394    394       M -> K (in HEMB).
FT                                /FTId=VAR_006601.
FT   VARIANT     395    395       F -> I (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017359.
FT   VARIANT     395    395       F -> L (in HEMB).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_017360.
FT   VARIANT     396    396       C -> F (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017361.
FT   VARIANT     396    396       C -> S (in HEMB; severe).
FT                                /FTId=VAR_006602.
FT   VARIANT     397    397       A -> P (in HEMB; mild; Hong Kong-11).
FT                                {ECO:0000269|PubMed:9590153}.
FT                                /FTId=VAR_017317.
FT   VARIANT     404    404       R -> T (in HEMB).
FT                                /FTId=VAR_006603.
FT   VARIANT     407    407       C -> R (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017362.
FT   VARIANT     407    407       C -> S (in HEMB; severe).
FT                                /FTId=VAR_006604.
FT   VARIANT     410    410       D -> H (in HEMB; Mechtal).
FT                                {ECO:0000269|PubMed:1346975}.
FT                                /FTId=VAR_017318.
FT   VARIANT     411    411       S -> G (in HEMB; Varel).
FT                                {ECO:0000269|PubMed:1346975}.
FT                                /FTId=VAR_017320.
FT   VARIANT     411    411       S -> I (in HEMB; Schmallenberg).
FT                                {ECO:0000269|PubMed:1346975}.
FT                                /FTId=VAR_017319.
FT   VARIANT     412    412       G -> E (in HEMB).
FT                                {ECO:0000269|PubMed:12588353}.
FT                                /FTId=VAR_017363.
FT   VARIANT     413    413       G -> R (in HEMB; moderate to severe).
FT                                {ECO:0000269|PubMed:7981722,
FT                                ECO:0000269|PubMed:9222764}.
FT                                /FTId=VAR_006605.
FT   VARIANT     414    414       P -> T (in HEMB; Bergamo).
FT                                {ECO:0000269|PubMed:12604421,
FT                                ECO:0000269|PubMed:2162822}.
FT                                /FTId=VAR_017321.
FT   VARIANT     419    419       V -> E (in HEMB; moderately severe).
FT                                {ECO:0000269|PubMed:8076946,
FT                                ECO:0000269|PubMed:8199596}.
FT                                /FTId=VAR_006606.
FT   VARIANT     424    424       F -> V (in HEMB).
FT                                {ECO:0000269|PubMed:9222764}.
FT                                /FTId=VAR_006607.
FT   VARIANT     426    426       T -> P (in HEMB; severe; Barcelos).
FT                                {ECO:0000269|PubMed:8257988}.
FT                                /FTId=VAR_006608.
FT   VARIANT     430    430       S -> T (in HEMB).
FT                                /FTId=VAR_006609.
FT   VARIANT     431    431       W -> G (in HEMB).
FT                                /FTId=VAR_006610.
FT   VARIANT     431    431       W -> R (in HEMB; moderate).
FT                                /FTId=VAR_006611.
FT   VARIANT     432    432       G -> S (in HEMB; severe).
FT                                /FTId=VAR_006612.
FT   VARIANT     432    432       G -> V (in HEMB; severe).
FT                                {ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006613.
FT   VARIANT     433    433       E -> A (in HEMB).
FT                                /FTId=VAR_006614.
FT   VARIANT     433    433       E -> K (in HEMB).
FT                                /FTId=VAR_006615.
FT   VARIANT     435    435       C -> Y (in HEMB).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_017364.
FT   VARIANT     436    436       A -> V (in HEMB; moderately severe;
FT                                Niigata). {ECO:0000269|PubMed:3243764}.
FT                                /FTId=VAR_006616.
FT   VARIANT     442    442       G -> E (in HEMB).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_017365.
FT   VARIANT     442    442       G -> R (in HEMB; severe; Angers).
FT                                {ECO:0000269|PubMed:2714791}.
FT                                /FTId=VAR_017322.
FT   VARIANT     443    443       I -> T (in HEMB; moderately severe; Long
FT                                Beach, Los Angeles and Vancouver).
FT                                {ECO:0000269|PubMed:1902289,
FT                                ECO:0000269|PubMed:3401602}.
FT                                /FTId=VAR_017323.
FT   VARIANT     445    445       T -> TIYT (in HEMB; severe; Lousada).
FT                                /FTId=VAR_006617.
FT   VARIANT     449    449       R -> Q (in HEMB; mild).
FT                                {ECO:0000269|PubMed:8076946}.
FT                                /FTId=VAR_006618.
FT   VARIANT     449    449       R -> W (in HEMB; mild).
FT                                {ECO:0000269|PubMed:12604421}.
FT                                /FTId=VAR_006619.
FT   VARIANT     450    450       Y -> C (in HEMB; severe).
FT                                {ECO:0000269|PubMed:9600455}.
FT                                /FTId=VAR_006620.
FT   VARIANT     453    453       W -> R (in HEMB).
FT                                {ECO:0000269|PubMed:2773937}.
FT                                /FTId=VAR_017324.
FT   VARIANT     454    454       I -> T (in HEMB; Italy).
FT                                {ECO:0000269|PubMed:9452115}.
FT                                /FTId=VAR_006621.
FT   VARIANT     461    461       T -> P (in dbSNP:rs4149751).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_014308.
FT   MUTAGEN     305    305       Y->F: Strongly increases enzyme activity
FT                                with a synthetic peptide substrate; when
FT                                associated with T-311; A-365 and T-391.
FT                                {ECO:0000269|PubMed:12444082}.
FT   MUTAGEN     311    311       K->T: Strongly increases enzyme activity
FT                                with a synthetic peptide substrate; when
FT                                associated with F-305; A-365 and T-391.
FT                                {ECO:0000269|PubMed:12444082}.
FT   MUTAGEN     312    312       Y->A: Strongly decreases enzyme activity
FT                                with a synthetic peptide substrate.
FT                                {ECO:0000269|PubMed:12444082}.
FT   MUTAGEN     391    391       Y->T: Strongly increases enzyme activity
FT                                with a synthetic peptide substrate; when
FT                                associated with F-305; T-311 and A-365.
FT                                {ECO:0000269|PubMed:12444082}.
FT   STRAND       50     52       {ECO:0000244|PDB:1NL0}.
FT   HELIX        60     64       {ECO:0000244|PDB:1NL0}.
FT   STRAND       65     67       {ECO:0000244|PDB:1CFH}.
FT   HELIX        71     75       {ECO:0000244|PDB:1NL0}.
FT   STRAND       78     80       {ECO:0000244|PDB:1NL0}.
FT   HELIX        81     90       {ECO:0000244|PDB:1NL0}.
FT   TURN         96     99       {ECO:0000244|PDB:1EDM}.
FT   STRAND      107    111       {ECO:0000244|PDB:1EDM}.
FT   STRAND      114    118       {ECO:0000244|PDB:1EDM}.
FT   TURN        125    128       {ECO:0000244|PDB:1IXA}.
FT   TURN        134    136       {ECO:0000244|PDB:2WPH}.
FT   HELIX       137    140       {ECO:0000244|PDB:2WPH}.
FT   STRAND      142    147       {ECO:0000244|PDB:2WPH}.
FT   STRAND      149    151       {ECO:0000244|PDB:2WPJ}.
FT   STRAND      153    156       {ECO:0000244|PDB:2WPH}.
FT   STRAND      161    163       {ECO:0000244|PDB:2WPH}.
FT   STRAND      165    168       {ECO:0000244|PDB:2WPI}.
FT   STRAND      170    176       {ECO:0000244|PDB:2WPH}.
FT   STRAND      187    189       {ECO:0000244|PDB:2WPJ}.
FT   STRAND      241    248       {ECO:0000244|PDB:2WPH}.
FT   STRAND      252    258       {ECO:0000244|PDB:2WPH}.
FT   STRAND      261    264       {ECO:0000244|PDB:2WPH}.
FT   HELIX       266    268       {ECO:0000244|PDB:2WPH}.
FT   STRAND      271    273       {ECO:0000244|PDB:2WPL}.
FT   STRAND      276    280       {ECO:0000244|PDB:2WPH}.
FT   STRAND      282    286       {ECO:0000244|PDB:1RFN}.
FT   STRAND      292    301       {ECO:0000244|PDB:2WPH}.
FT   TURN        303    306       {ECO:0000244|PDB:2WPH}.
FT   STRAND      307    310       {ECO:0000244|PDB:2WPH}.
FT   TURN        311    314       {ECO:0000244|PDB:3KCG}.
FT   STRAND      317    323       {ECO:0000244|PDB:2WPH}.
FT   HELIX       339    347       {ECO:0000244|PDB:2WPH}.
FT   STRAND      350    360       {ECO:0000244|PDB:2WPH}.
FT   STRAND      370    377       {ECO:0000244|PDB:2WPH}.
FT   HELIX       379    384       {ECO:0000244|PDB:2WPH}.
FT   STRAND      394    398       {ECO:0000244|PDB:2WPH}.
FT   STRAND      414    419       {ECO:0000244|PDB:2WPH}.
FT   STRAND      422    431       {ECO:0000244|PDB:2WPH}.
FT   STRAND      433    436       {ECO:0000244|PDB:2WPH}.
FT   STRAND      442    446       {ECO:0000244|PDB:2WPH}.
FT   HELIX       447    450       {ECO:0000244|PDB:2WPH}.
FT   HELIX       451    457       {ECO:0000244|PDB:2WPH}.
SQ   SEQUENCE   461 AA;  51778 MW;  C4720C1234477EF5 CRC64;
     MQRVNMIMAE SPGLITICLL GYLLSAECTV FLDHENANKI LNRPKRYNSG KLEEFVQGNL
     ERECMEEKCS FEEAREVFEN TERTTEFWKQ YVDGDQCESN PCLNGGSCKD DINSYECWCP
     FGFEGKNCEL DVTCNIKNGR CEQFCKNSAD NKVVCSCTEG YRLAENQKSC EPAVPFPCGR
     VSVSQTSKLT RAETVFPDVD YVNSTEAETI LDNITQSTQS FNDFTRVVGG EDAKPGQFPW
     QVVLNGKVDA FCGGSIVNEK WIVTAAHCVE TGVKITVVAG EHNIEETEHT EQKRNVIRII
     PHHNYNAAIN KYNHDIALLE LDEPLVLNSY VTPICIADKE YTNIFLKFGS GYVSGWGRVF
     HKGRSALVLQ YLRVPLVDRA TCLRSTKFTI YNNMFCAGFH EGGRDSCQGD SGGPHVTEVE
     GTSFLTGIIS WGEECAMKGK YGIYTKVSRY VNWIKEKTKL T
//
